Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gliatech Adcon

This article was originally published in The Gray Sheet

Executive Summary

All regulatory submissions related to the anti-adhesion technology over the next two years must be reviewed and certified by an independent auditor prior to submission to FDA under an agreement resolving issues raised in a December 2000 application integrity policy (AIP) letter from the agency. Gliatech plans to auction its Adcon assets as part of bankruptcy proceedings; the device is not available in the U.S. (1"The Gray Sheet" Sept. 30, 2002, In Brief)...

You may also be interested in...



Gliatech bankruptcy

Cleveland biosurgery firm sells Adcon Gel assets to Wright Medical Group Jan. 3 for $8.4 mil. plus future royalties. The pact is expected to close in the first quarter, pending bankruptcy court approval. Discussions with undisclosed parties are ongoing for a sale of Gliatech's Adcon Solution assets (1"The Gray Sheet" Oct. 14, 2002, In Brief)...

Gliatech Adcon

Potential buyers of the firm's flagship anti-adhesion technology will have the option of finishing a 16-site pivotal trial to support gynecological and pelvic indications. The technology, including solution and gel formulation, is being auctioned as part of Gliatech's ongoing chapter 11 bankruptcy proceedings the firm filed in May (1"The Gray Sheet" May 6, 2002, p. 10). The Cleveland company had started a modular PMA submission for the pivotal trial indications, but the process was halted following receipt of a December 2000 application integrity policy (AIP) letter from FDA (2"The Gray Sheet" Jan. 1, 2001, p. 5). Gliatech claims it "has substantially completed its obligations" under the AIP and is "working toward the revocation of the company's AIP status." The firm has retained Adams, Harkness & Hill to manage the auction...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel